Tvardi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	19.85	20.73	31.61	51.78	63.74	13.45
Short-Term Investments	5.13	10.08	-	48.98	81.66	153.58
Cash & Short-Term Investments	24.98	30.81	31.61	100.76	145.4	167.04
Cash Growth	-26.99%	-2.54%	-68.62%	-30.70%	-12.95%	-7.68%
Accounts Receivable	-	-	-	2.77	3.26	-
Other Receivables	-	-	-	1.25	1.19	1.15
Total Trade Receivables	-	-	-	4.02	4.45	1.15
Inventory	-	-	-	2.82	2.38	2.58
Other Current Assets	0.35	0.73	0.07	8.56	16.68	2.52
Total Current Assets	25.33	31.54	31.69	116.16	168.91	173.29
Net Property, Plant & Equipment	0.17	0.2	0.3	8.19	1.98	3.6
Other Intangible Assets	0.31	0.32	0.39	-	-	-
Long-Term Investments	-	-	-	-	11.35	69.75
Other Long-Term Assets	0.02	0.02	2.83	1.5	-	0.41
Total Assets	25.82	32.07	35.2	125.84	182.24	247.06
Accounts Payable	4.62	3.22	2.19	25.59	21.54	15.86
Accrued Expenses	6.52	7.71	8.08	-	-	-
Current Portion of Leases	0.12	0.12	0.1	-	1.92	1.76
Total Current Liabilities	11.26	11.04	10.37	25.59	23.46	17.62
Long-Term Leases	0.05	0.09	0.2	6.09	-	1.92
Other Long-Term Liabilities	-	-	30.26	37.08	-	-
Total Long-Term Liabilities	0.05	0.09	30.46	43.17	-	1.92
Total Liabilities	11.31	11.13	40.83	68.76	23.46	19.53
Common Stock	0.01	0.01	0	0.01	0.05	0.05
Additional Paid-in Capital	131.75	131.38	1.1	742.09	726.63	708.59
Accumulated Other Comprehensive Income	0	0.01	-	-0.26	-1.67	-0.36
Retained Earnings	-117.25	-110.45	-92.24	-684.75	-566.23	-480.76
Total Common Shareholders' Equity	14.51	20.95	-91.13	57.09	158.78	227.52
Minority Interest	-	-	85.5	-	-	-
Shareholders' Equity	14.51	20.95	-5.63	57.09	158.78	227.52
Total Liabilities & Equity	25.82	32.07	35.2	125.84	182.24	247.06
Total Debt	0.17	0.2	0.3	6.09	1.92	3.67
Net Cash (Debt)	24.81	30.61	31.31	94.67	143.48	163.36
Net Cash Growth	-18.96%	-2.24%	-66.93%	-34.02%	-12.17%	-7.00%
Net Cash Per Share	2.71	3.93	12.16	63.52	96.27	115.95
Book Value	14.51	20.95	-91.13	57.09	158.78	227.52
Book Value Per Share	1.59	2.69	-35.40	38.30	106.54	161.49
Tangible Book Value	14.2	20.62	-91.52	57.09	158.78	227.52
Tangible Book Value Per Share	1.55	2.65	-35.55	38.30	106.54	161.49

SEC Filings: 10-K · 10-Q